{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T02:46:17Z","timestamp":1782269177532,"version":"3.54.5"},"reference-count":36,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Background\/Objectives: Lisocabtagene maraleucel (liso-cel) is a CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy approved for relapsed or refractory large B-cell lymphoma (R\/R LBCL). However, most published meta-analyses of CAR-T therapy in LBCL pool data across products, limiting product-specific interpretation. Methods: We conducted a systematic review and meta-analysis of clinical trials and retrospective real-world studies evaluating liso-cel monotherapy in R\/R LBCL. The primary endpoint was the overall response rate (ORR). Secondary endpoints included complete response (CR), incidence of grade \u2265 3 adverse events, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), overall mortality rate (OMR), disease progression-related mortality, and adverse event-related mortality. Pooled proportions were estimated using random-effects models. Results: Eleven studies including 1206 patients were analyzed, comprising five clinical trials and six real-world retrospective cohorts. The pooled ORR was 78%, and the pooled CR rate was 60%. The pooled OMR was 38%, with a disease progression-related mortality of 28% and an adverse event-related mortality of 4%. Severe (grade \u2265 3) CRS and ICANS occurred in 2% and 8%, respectively. Severe (grade \u2265 3) hematologic toxicities were frequent, particularly neutropenia, thrombocytopenia, and anemia. Conclusions: Liso-cel monotherapy demonstrated high pooled response rates and low pooled incidences of severe CRS and ICANS across clinical trials and real-world settings in R\/R LBCL. Severe ICANS, although uncommon, remains clinically meaningful, and severe hematologic toxicities were frequent and warrant careful monitoring and supportive care. These findings provide product-specific benchmarks for liso-cel in R\/R LBCL.<\/jats:p>","DOI":"10.3390\/hematolrep18040043","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T01:03:23Z","timestamp":1782263003000},"page":"43","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Lisocabtagene Maraleucel in Relapsed or Refractory Large B-Cell Lymphoma: A Product-Specific Systematic Review and Meta-Analysis of Clinical Trials and Real-World Studies"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2824-4202","authenticated-orcid":false,"given":"Jerry","family":"Qi","sequence":"first","affiliation":[{"name":"Department of Medicine, Loma Linda University Medical Center, 11234 Anderson St., Loma Linda, CA 92354, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, San Francisco, Fresno Campus, 155 N. Fresno Street, Fresno, CA 93701, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidhi","family":"Kejriwal","sequence":"additional","affiliation":[{"name":"School of Medicine, University of California, Riverside, 900 University Ave., Riverside, CA 92521, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9501-9226","authenticated-orcid":false,"given":"Austin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Medicine, Loma Linda University Medical Center, 11234 Anderson St., Loma Linda, CA 92354, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2417-7981","authenticated-orcid":false,"given":"Kareem","family":"Latif","sequence":"additional","affiliation":[{"name":"Department of Medicine, Loma Linda University Medical Center, 11234 Anderson St., Loma Linda, CA 92354, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6875-8387","authenticated-orcid":false,"given":"Sarkis","family":"Dagley","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Central Florida, 6850 Lake Nona Blvd., Orlando, FL 32827, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojtaba","family":"Akhtari","sequence":"additional","affiliation":[{"name":"Division of Transplant, Cellular Therapy, and Hematological Malignancies, Department of Medicine, Loma Linda University Medical Center, 11234 Anderson St., Loma Linda, CA 92354, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e3202","DOI":"10.1002\/hon.3202","article-title":"Diffuse large B-cell lymphoma","volume":"42","author":"Barraclough","year":"2024","journal-title":"Hematol. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1111\/bjh.20129","article-title":"Management of relapsed or refractory large B-cell lymphoma: A British Society for Haematology Guideline","volume":"206","author":"Chaganti","year":"2025","journal-title":"Br. J. Haematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1186\/s12967-023-04372-4","article-title":"Complexities in comparing the impact of costimulatory domains on approved CD19 CAR functionality","volume":"21","author":"Smith","year":"2023","journal-title":"J. Transl. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood.2023020854","article-title":"Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001","volume":"143","author":"Abramson","year":"2024","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: Primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_8","unstructured":"Wells, G.A., Shea, B., O\u2019Connell, D., Peterson, J., Welch, V., Losos, M., and Tugwell, P. (2026, May 26). The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses; Ottawa Hospital Research Institute: Ottawa, ON, Canada. Available online: https:\/\/ohri.ca\/en\/who-we-are\/core-facilities-and-platforms\/ottawa-methods-centre\/newcastle-ottawa-scale."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4889","DOI":"10.1002\/cam4.4820","article-title":"Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma","volume":"11","author":"Makita","year":"2022","journal-title":"Cancer Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"6931","DOI":"10.1182\/blood-2023-184637","article-title":"Efficacy of lisocabtagene maraleucel for relapsed or refractory aggressive B cell lymphoma in our hospital","volume":"142","author":"Kaji","year":"2023","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1182\/blood-2024-199723","article-title":"Real-world (RW) outcomes of lisocabtagene maraleucel (liso-cel) as second-line (2L) therapy in patients (pts) with relapsed or refractory (R\/R) large B-cell lymphoma (LBCL): First results from the center for international blood and marrow transplant research (CIBMTR) registry","volume":"144","author":"Bobillo","year":"2024","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6114","DOI":"10.1182\/bloodadvances.2024013254","article-title":"OUTREACH: Phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R\/R LBCL","volume":"8","author":"Linhares","year":"2024","journal-title":"Blood Adv."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/j.jtct.2023.12.071","article-title":"Multicenter, real-world study in patients with R\/R large B-cell lymphoma (LBCL) who received lisocabtagene maraleucel (liso-cel) in the United States (US)","volume":"30","author":"Palomba","year":"2024","journal-title":"Transplant. Cell Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/bloodadvances.2024014164","article-title":"Lisocabtagene maraleucel for relapsed\/refractory large B-cell lymphoma: A cell therapy consortium real-world analysis","volume":"9","author":"Riedell","year":"2025","journal-title":"Blood Adv."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"S227","DOI":"10.1016\/j.jtct.2025.01.348","article-title":"Outcomes of standard of care (SOC) lisocabtagene maraleucel (liso-cel) in patients (Pts) with relapsed or refractory large B-cell lymphoma (LBCL) and secondary CNS (sCNS) involvement from the center for international blood and marrow transplant research (CIBMTR) registry","volume":"31","author":"Ahmed","year":"2025","journal-title":"Transplant. Cell Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1182\/bloodadvances.2024015262","article-title":"Lisocabtagene maraleucel for R\/R LBCL in patients not intended for HSCT: Final results of the phase 2 PILOT study","volume":"9","author":"Sehgal","year":"2025","journal-title":"Blood Adv."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S231","DOI":"10.1016\/j.jtct.2025.01.353","article-title":"Multicenter real-world study in patients with relapsed\/refractory large B-cell lymphoma who received lisocabtagene maraleucel; JSCT-CART23 study from Japan study group for cell therapy and transplantation","volume":"31","author":"Kato","year":"2025","journal-title":"Transplant. Cell Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Sterner, R.C., and Sterner, R.M. (2022). Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.879608"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/ejh.14074","article-title":"Chimeric antigen receptor T-cell therapy in hematologic malignancies: Successes, challenges, and opportunities","volume":"112","author":"Ho","year":"2024","journal-title":"Eur. J. Haematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/ejh.14076","article-title":"CAR-T cell therapy in hematological malignancies: Where are we now and where are we heading for?","volume":"112","author":"Khan","year":"2024","journal-title":"Eur. J. Haematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","article-title":"A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains","volume":"18","author":"Cappell","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"103267","DOI":"10.1016\/j.eclinm.2025.103267","article-title":"Treatment-related adverse events of chimeric antigen receptor-T therapies for cancers in clinical trials: A systematic review and meta-analysis","volume":"84","author":"Zhu","year":"2025","journal-title":"eClinicalMedicine"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.jcyt.2022.03.013","article-title":"Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19+ hematologic indications","volume":"24","author":"Teoh","year":"2022","journal-title":"Cytotherapy"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e70726","DOI":"10.1002\/cam4.70726","article-title":"CAR-T Cell Manufacturing for Hematological and Solid Tumors: From the Preclinical to Clinical Point of View","volume":"14","author":"Capolla","year":"2025","journal-title":"Cancer Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2352-3026(24)00077-2","article-title":"Immune effector cell-associated haematotoxicity after CAR T-cell therapy: From mechanism to management","volume":"11","author":"Rejeski","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1182\/hematology.2023000472","article-title":"Recognizing, defining, and managing CAR-T hematologic toxicities","volume":"2023","author":"Rejeski","year":"2023","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"165.e1","DOI":"10.1016\/j.jtct.2022.12.020","article-title":"Apoptosis of Hematopoietic Stem Cells Contributes to Bone Marrow Suppression Following Chimeric Antigen Receptor T Cell Therapy","volume":"29","author":"Read","year":"2023","journal-title":"Transplant. Cell Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: A model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"key":"ref_32","first-page":"2460","article-title":"How I treat cytopenias after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41375-022-01739-2","article-title":"Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma","volume":"37","author":"Fein","year":"2023","journal-title":"Leukemia"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.3324\/haematol.2024.285255","article-title":"Sequencing of cellular therapy and bispecific antibodies for the management of diffuse large B-cell lymphoma","volume":"109","author":"Melody","year":"2024","journal-title":"Haematologica"}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/18\/4\/43\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T01:46:47Z","timestamp":1782265607000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/18\/4\/43"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["hematolrep18040043"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep18040043","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]}}}